Kana Fujii
Kyushu University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Kana Fujii.
American Journal of Hypertension | 2017
Kana Fujii; Keita Saku; Takuya Kishi; Yasuhiro Oga; Takeshi Tohyama; Takuya Nishikawa; Takafumi Sakamoto; Masataka Ikeda; Tomomi Ide; Hiroyuki Tsutsui; Kenji Sunagawa
BACKGROUND Hypertension is a major cause of heart failure. Excessive sympathoexcitation in patients with heart failure leads to poor prognosis. Since carotid body denervation (CBD) has been shown to reduce sympathetic nerve activity in animal models of hypertension and heart failure, we examined if bilateral CBD attenuates the progression of hypertensive heart failure and improves survival. METHODS We randomly allocated Dahl salt-sensitive rats fed a high-salt diet from 6 weeks of age into CBD (n = 31) and sham-operation (SHAM; n = 50) groups, and conducted CBD or SHAM at 7 weeks of age. We examined the time course of 24-hour urinary norepinephrine (uNE) excretion, blood pressure (BP) and the percent fractional shortening assessed by echocardiography, and estimated the pressure-natriuresis relationship at 14 weeks of age. Finally, we assessed hemodynamics, histological findings, and survival at 16 weeks of age. RESULTS Compared to SHAM, CBD significantly reduced 24-hour uNE at 12, 14, and 16 weeks of age, shifted the pressure-natriuresis relationship leftward without changing its slope, and attenuated the increase in BP. CBD preserved percent fractional shortening (34.2 ± 1.2 vs. 29.1 ± 1.3%, P < 0.01) and lowered left ventricular end-diastolic pressure (5.0 ± 0.9 vs. 9.0 ± 1.4 mm Hg, P < 0.05). Furthermore, CBD significantly attenuated myocardial hypertrophy (P < 0.01) and fibrosis (P < 0.01). Consequently, CBD markedly improved survival (relative risk reduction: 64.8%). CONCLUSIONS CBD attenuated the progression of hypertension and worsening of heart failure possibly through sympathoinhibition, and markedly improved survival in a rat model of hypertensive heart failure.
The FASEB Journal | 2015
Masako Shinoda; Keita Saku; Kohtaro Abe; Takako Takehara; Yukimitu Kuwabara; Keimei Yoshida; Kana Fujii; Akiko Nishizaki; Yasuhiro Oga; Kenji Sunagawa
The FASEB Journal | 2015
Yasuhiro Oga; Takuya Kishi; Keita Saku; Takamori Kakino; Akiko Nishizaki; Takahiro Arimura; Kana Fujii; Takeshi Tohyama; Takuya Nishikawa; Kenji Sunagawa
The FASEB Journal | 2015
Kana Fujii; Keita Saku; Takuya Kishi; Takako Takehara; Takuya Akashi; Yasuhiro Oga; Akiko Nishizaki; Takahiro Arimura; Takeshi Tohyama; Takuya Nishikawa; Kenji Sunagawa
Journal of Cardiac Failure | 2015
Yasuhiro Oga; Takuya Kishi; Keita Saku; Akiko Nishizaki; Takahiro Arimura; Kana Fujii; Takeshi Tohyama; Takuya Nishikawa; Tomomi Ide; Kenji Sunagawa
Journal of Cardiac Failure | 2015
Kana Fujii; Keita Saku; Yasuhiro Oga; Akiko Nishizaki; Takako Takehara; Takuya Akashi; Takuya Kishi; Kenji Sunagawa
Transactions of Japanese Society for Medical and Biological Engineering | 2014
Takahiro Arimura; Keita Saku; Takamori Kakino; Takuya Akashi; Takako Takehara; Akiko Nishizaki; Yasuhiro Oga; Masataka Ikeda; Kana Fujii; Tomomi Ide; Takuya Kishi; Kenji Sunagawa
Transactions of Japanese Society for Medical and Biological Engineering | 2014
Kana Fujii; Takahiro Arimura; Keita Saku; Takamori Kakino; Takuya Akashi; Tomomi Ide; Takuya Kishi; Kinji Sunagawa
The FASEB Journal | 2014
Keita Saku; Takuya Kishi; Kana Fujii; Akiko Nishizaki; Takako Takehara; Takuya Akashi; Takamori Kakino; Masataka Ikeda; Yasuhiro Oga; Takahiro Arimura; Masako Shinoda; Tomomi Ide; Kenji Sunagawa
The FASEB Journal | 2014
Takahiro Arimura; Keita Saku; Takamori Kakino; Takuya Akashi; Takako Takehara; Akiko Nishizaki; Yasuhiro Oga; Masataka Ikeda; Kana Fujii; Tomomi Ide; Takuya Kishi; Kenji Sunagawa